Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Pharmacological Management of Osteoporosis in Rheumatoid Arthritis Patients: A Review of the Literature and Practical Guide.

Raterman HG, Lems WF.

Drugs Aging. 2019 Sep 21. doi: 10.1007/s40266-019-00714-4. [Epub ahead of print]

PMID:
31541358
2.

Current Treatments and New Developments in the Management of Glucocorticoid-induced Osteoporosis.

Raterman HG, Bultink IEM, Lems WF.

Drugs. 2019 Jul;79(10):1065-1087. doi: 10.1007/s40265-019-01145-6. Review.

PMID:
31201710
3.

Common mechanisms and holistic care in atherosclerosis and osteoporosis.

Szekanecz Z, Raterman HG, Pethő Z, Lems WF.

Arthritis Res Ther. 2019 Jan 10;21(1):15. doi: 10.1186/s13075-018-1805-7. Review.

4.

Critical issues and current challenges in osteoporosis and fracture prevention. An overview of unmet needs.

Lems WF, Raterman HG.

Ther Adv Musculoskelet Dis. 2017 Dec;9(12):299-316. doi: 10.1177/1759720X17732562. Epub 2017 Oct 27. Review.

5.

B-cell imaging with zirconium-89 labelled rituximab PET-CT at baseline is associated with therapeutic response 24 weeks after initiation of rituximab treatment in rheumatoid arthritis patients.

Bruijnen S, Tsang-A-Sjoe M, Raterman H, Ramwadhdoebe T, Vugts D, van Dongen G, Huisman M, Hoekstra O, Tak PP, Voskuyl A, van der Laken C.

Arthritis Res Ther. 2016 Nov 18;18(1):266.

6.

Increased progression of carotid intima media thickness in thyroid peroxidase antibodies-positive rheumatoid arthritis patients.

Raterman HG, Voskuyl AE, Simsek S, Schreurs MW, van Hoogstraten IM, Peters MJ, van Halm VP, Dijkmans BA, Lips P, Lems WF, Nurmohamed MT.

Eur J Endocrinol. 2013 Oct 21;169(6):751-7. doi: 10.1530/EJE-13-0394. Print 2013 Dec.

PMID:
24005313
7.

A non-inferiority trial of an attenuated combination strategy ('COBRA-light') compared to the original COBRA strategy: clinical results after 26 weeks.

den Uyl D, ter Wee M, Boers M, Kerstens P, Voskuyl A, Nurmohamed M, Raterman H, van Schaardenburg D, van Dillen N, Dijkmans B, Lems W.

Ann Rheum Dis. 2014 Jun;73(6):1071-8. doi: 10.1136/annrheumdis-2012-202818. Epub 2013 Apr 19.

8.

HDL protein composition alters from proatherogenic into less atherogenic and proinflammatory in rheumatoid arthritis patients responding to rituximab.

Raterman HG, Levels H, Voskuyl AE, Lems WF, Dijkmans BA, Nurmohamed MT.

Ann Rheum Dis. 2013 Apr;72(4):560-5. doi: 10.1136/annrheumdis-2011-201228. Epub 2012 May 15.

PMID:
22589377
9.

Hypothyroidism in rheumatoid arthritis--to screen or not to screen?

Raterman HG, Nurmohamed MT.

J Rheumatol. 2012 May;39(5):885-6. doi: 10.3899/jrheum.120015. No abstract available.

PMID:
22550004
10.

The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients.

Raterman HG, Vosslamber S, de Ridder S, Nurmohamed MT, Lems WF, Boers M, van de Wiel M, Dijkmans BA, Verweij CL, Voskuyl AE.

Arthritis Res Ther. 2012 Apr 27;14(2):R95. doi: 10.1186/ar3819.

11.

Coexistence of hypothyroidism with inflammatory arthritis is associated with cardiovascular disease in women.

Raterman HG, Nielen MM, Peters MJ, Verheij RA, Nurmohamed MT, Schellevis FG.

Ann Rheum Dis. 2012 Jul;71(7):1216-8. doi: 10.1136/annrheumdis-2011-200836. Epub 2012 Mar 14.

PMID:
22419774
12.

Osteopenia: a diagnostic and therapeutic challenge.

Lems WF, Raterman HG, van den Bergh JP, Bijlsma HW, Valk NK, Zillikens MC, Geusens P.

Curr Osteoporos Rep. 2011 Sep;9(3):167-72. doi: 10.1007/s11914-011-0062-3.

13.

Pharmacological induction of interferon type I activity following treatment with rituximab determines clinical response in rheumatoid arthritis.

Vosslamber S, Raterman HG, van der Pouw Kraan TC, Schreurs MW, von Blomberg BM, Nurmohamed MT, Lems WF, Dijkmans BA, Voskuyl AE, Verweij CL.

Ann Rheum Dis. 2011 Jun;70(6):1153-9. doi: 10.1136/ard.2010.147199. Epub 2011 Mar 27.

PMID:
21444302
14.

(Sub)clinical cardiovascular disease is associated with increased bone loss and fracture risk; a systematic review of the association between cardiovascular disease and osteoporosis.

den Uyl D, Nurmohamed MT, van Tuyl LH, Raterman HG, Lems WF.

Arthritis Res Ther. 2011 Jan 17;13(1):R5. doi: 10.1186/ar3224. Review.

15.

Improvement of thyroid function in hypothyroid patients with rheumatoid arthritis after 6 months of adalimumab treatment: a pilot study.

Raterman HG, Jamnitski A, Lems WF, Voskuyl AE, Dijkmans BA, Bos WH, Simsek S, Lips P, van de Stadt RJ, de Koning MH, Nurmohamed MT.

J Rheumatol. 2011 Feb;38(2):247-51. doi: 10.3899/jrheum.100488. Epub 2010 Nov 15.

PMID:
21078720
16.

Endothelial dysfunction, inflammation, and apoptosis in diabetes mellitus.

van den Oever IA, Raterman HG, Nurmohamed MT, Simsek S.

Mediators Inflamm. 2010;2010:792393. doi: 10.1155/2010/792393. Epub 2010 Jun 15. Review.

17.

Improvement of work ability, quality of life, and fatigue in patients with rheumatoid arthritis treated with adalimumab.

Herenius MM, Hoving JL, Sluiter JK, Raterman HG, Lems WF, Dijkmans BA, Tak PP, Nurmohamed MT, Voskuyl AE, Frings-Dresen MH.

J Occup Environ Med. 2010 Jun;52(6):618-21. doi: 10.1097/JOM.0b013e3181de8357.

PMID:
20523240
18.

Work ability: a new outcome measure in rheumatoid arthritis?

Raterman HG, Hoving JL, Nurmohamed MT, Herenius MM, Sluiter JK, Lems WF, Tak PP, Dijkmans BA, Twisk J, Frings-Dresen MH, Voskuyl AE.

Scand J Rheumatol. 2010 Mar;39(2):127-31. doi: 10.3109/03009740903447044.

PMID:
20059369
19.

Use of methotrexate therapy is not associated with decreased prevalence of metabolic syndrome.

Raterman HG, Voskuyl AE, Dijkmans BA, Nurmohamed MT.

Arthritis Res Ther. 2009;11(5):413; author reply 414. doi: 10.1186/ar2805. Epub 2009 Sep 21. No abstract available.

20.

Increased cardiovascular disease in patients with inflammatory arthritis in primary care: a cross-sectional observation.

Peters MJ, Nielen MM, Raterman HG, Verheij RA, Schellevis FG, Nurmohamed MT.

J Rheumatol. 2009 Sep;36(9):1866-8. doi: 10.3899/jrheum.090010. Epub 2009 Jul 31.

PMID:
19648308
21.

Rituximab and thyroid function.

Raterman HG, Simsek S, Lems WF, Meesters EW, Dijkmans BA, Nurmohamed MT.

Arch Intern Med. 2009 Jun 8;169(11):1073-4. doi: 10.1001/archinternmed.2009.116. No abstract available.

PMID:
19506179
22.

The metabolic syndrome is amplified in hypothyroid rheumatoid arthritis patients: a cross-sectional study.

Raterman HG, van Eijk IC, Voskuyl AE, Peters MJ, Dijkmans BA, van Halm VP, Simsek S, Lems WF, Nurmohamed MT.

Ann Rheum Dis. 2010 Jan;69(1):39-42. doi: 10.1136/ard.2008.100776.

PMID:
19103637
23.

Increased prevalence of antithyroid antibodies in rheumatoid arthritis (RA) patients with a low prevalence of hormonal alterations.

Raterman HG, Van Halm VP, Voskuyl AE, Simsek S, Dijkmans BA, Nurmohamed MT.

Autoimmunity. 2008 Aug;41(5):337. No abstract available.

PMID:
18578079
24.

Rheumatoid arthritis is associated with a high prevalence of hypothyroidism that amplifies its cardiovascular risk.

Raterman HG, van Halm VP, Voskuyl AE, Simsek S, Dijkmans BA, Nurmohamed MT.

Ann Rheum Dis. 2008 Feb;67(2):229-32. Epub 2007 Jun 8.

PMID:
17557891

Supplemental Content

Loading ...
Support Center